Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02594384
Title A Phase I Dose Escalation Study A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)
Acronym LAM-002A/NHL
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Lam Therapeutics Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.